Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi

scientific article published on 9 December 2004

Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/426398
P8608Fatcat IDrelease_7wu6zgb65je2ljsykebpbkwpg4
P698PubMed publication ID15609237
P5875ResearchGate publication ID8121305

P50authorJean-Francois TrapeQ21340358
Cheikh SokhnaQ61809634
Adama TallQ80329231
Ronald PerrautQ88302312
Laurence MarramaQ94553982
Shirley LongacreQ114440098
P2093author name stringOdile Mercereau-Puijalon
Pierre Nabeth
Babacar Diouf
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectSenegalQ1041
malariaQ12156
antibodyQ79460
Plasmodium falciparumQ311383
P304page(s)264-271
P577publication date2004-12-09
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleAntibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi
P478volume191

Reverse relations

cites work (P2860)
Q42581710A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.
Q36625367A review of human vaccine research and development: malaria
Q34955461Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response
Q33380204Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum
Q35739071Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children
Q34334187Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum
Q36393772Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™).
Q37191417Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure
Q35901099Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals
Q36169093Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine candidate induce antibody-dependent respiratory burst in human neutrophils
Q35010158Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines
Q47996539Antibody response to allelic variants of 19kDa fragment of MSP-1: recognition of a variant and protection associated with ethnicity in Assam, India
Q36800846Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India
Q33380213Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults
Q48035058Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development
Q46471407Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria
Q33927906Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria
Q35456892Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies
Q36594057Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria
Q36391845Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?
Q33548663Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies
Q34460065Comparative analysis of IgG responses to Plasmodium falciparum MSP1p19 and PF13-DBL1α1 using ELISA and a magnetic bead-based duplex assay (MAGPIX®-Luminex) in a Senegalese meso-endemic community
Q90300290Complement in malaria immunity and vaccines
Q38089185Development of influenza virosome-based synthetic malaria vaccines
Q37597218Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1
Q37684687Dramatic declines in seropositivity as determined with crude extracts of Plasmodium falciparum schizonts between 2000 and 2010 in Dielmo and Ndiop, Senegal
Q34540211Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites
Q37598139Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections
Q36838314How Should Antibodies against P. falciparum Merozoite Antigens Be Measured?
Q37382587How might infant and paediatric immune responses influence malaria vaccine efficacy?
Q36123104Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults
Q50062994Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
Q47912581IgG responses to candidate malaria vaccine antigens in the urban area of Dakar (Senegal): evolution according to age and parasitemia in patients with mild symptoms
Q89559305Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
Q37099503Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness
Q34612788Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized
Q33613892In vitro growth-inhibitory activity and malaria risk in a cohort study in mali
Q36615170Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine
Q33305467Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.
Q36292890Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission in peri-urban area of Cote d'Ivoire between 2010 and 2013.
Q36219634Malaria vaccines in development
Q33939405Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay
Q31169310Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria
Q58761801Optimization of a magnetic bead-based assay (MAGPIX-Luminex) for immune surveillance of exposure to malaria using multiple Plasmodium antigens and sera from different endemic settings
Q36826951Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Q35532952Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria
Q39085988Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes
Q35944117Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria
Q92664225Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort
Q35762375Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies
Q33510819Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting
Q90464578Practical example of multiple antibody screening for evaluation of malaria control strategies
Q33743450Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24
Q33282524Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum
Q46299460Profiles of IgG responses against CSP, GLURP and LSA-3NR2 in urban malaria (Dakar): relations with haemoglobin levels and parasite densities
Q34081745Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans
Q34653470Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C.
Q36639261Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Q34189972Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic
Q33793094Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities
Q36304234Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine
Q28740432T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines
Q57293070Taking Sharper Pictures of Malaria with Combined Antibodies to Measure Exposure Recency Assays
Q36728063Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children
Q61799382Targets of complement-fixing antibodies in protective immunity against malaria in children
Q46517899The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan
Q33512926The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria
Q33526349The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis
Q34060022Transplacentally transferred functional antibodies against Plasmodium falciparum decrease with age.
Q47114766Unexpected high circulation of Plasmodium vivax in asymptomatic children from Kédougou, southeastern Senegal

Search more.